Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (672)	5/10/1999 10:33:00 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

I guess some of the recent news are starting to get "assimilated" Wait for the conference and for any possible report on "cancer vaccines". In the mean time keep very tightly buckled up!!! Leona Holmberg, M.D., Ph.D., Brenda Sandmaier, M.D., and co-investigators at the Fred Hutchinson Cancer Research Center, will be presenting data from a clinical trial of THERATOPE® cancer vaccine in patients with breast and ovarian cancers following hematopoietic stem cell transplant. Separately, Charles Vogel, M.D., FACP, Columbia Cancer Research Network, has been informed that an abstract concerning the use of THERATOPE® vaccine in Biomira's multi-center bridging study in women with metastatic breast cancer following first-line chemotherapy, was accepted for publication in the 1999 ASCO Proceedings. The bridging study was carried out before the Company initiated its pivotal Phase III trial currently underway.